Stay updated on KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial

Sign up to get notified when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Sponsor name updated from Karuna Therapeutics to Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
    Difference
    0.1%
    Check dated 2026-04-01T02:58:41.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Additions include new study identifiers, IPD sharing details, expanded inclusion criteria (MRI/CT within 5 years, age 55-90, study partner), and new endpoints (NPI-C H+D, CGI-S, responder rate) as well as the Placebo arm and numerous global sites. Deletions remove CMAI-related outcome information (CMAI score and its description).
    Difference
    1%
    Check dated 2026-03-24T21:28:23.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-09T14:28:51.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed, replacing the previous v3.4.1. This update does not alter study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-14T14:15:56.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    A minor platform revision entry was added: Revision: v3.4.1, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-07T08:55:54.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    Introduced a glossary display option (Show glossary) and updated page metadata to show 'Last Update Submitted that Met QC Criteria' and Revision: v3.4.0. The previous QC label usage and 'No FEAR Act Data' wording were adjusted.
    Difference
    0.1%
    Check dated 2026-01-24T06:07:02.000Z thumbnail image

Stay in the know with updates to KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.